ConjuLink™ UGT Fluorometric Activity Assay / Ligand Interaction Kit

CAT#: ITS-0326-WB8
Product Type: Assay Kit
Species: General (All species)
Target: UDP-glucuronosyltransferase (UGT) enzymes
Brand: ConjuLink™
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Measures UDP-glucuronosyltransferase activity and screens compound interactions using a sensitive fluorometric assay.
Brand
ConjuLink™
Development Stage
ADME
ADME Research Domain
Metabolism
Description
ConjuLink™ UGT Fluorometric Activity Assay / Ligand Interaction Kit enables rapid quantification of UDP-glucuronosyltransferase (UGT) activity and evaluation of compound interactions with Phase II conjugation enzymes. Using a fluorogenic substrate and optimized reaction system, the assay allows sensitive detection of glucuronidation activity in microsomes, recombinant enzymes, or cellular preparations, supporting drug metabolism studies and inhibitor screening.
Features
Fluorogenic substrate generates a measurable fluorescent signal following glucuronidation, enabling sensitive and quantitative monitoring of UGT enzymatic activity.
Optimized assay chemistry supports reliable detection of enzyme activity and ligand-dependent modulation across recombinant enzymes, microsomes, and cell lysates.
Microplate-based format allows scalable screening of potential inhibitors, activators, or interacting compounds affecting glucuronidation pathways.
Pre-optimized reagents and reaction conditions ensure consistent performance and reproducible metabolic profiling across drug discovery workflows.
Process Relevance
Evaluates UGT-mediated conjugation and compound interactions to predict metabolic clearance and drug-drug interaction risk.
Application Stage
Drug discovery, ADME profiling, metabolic enzyme characterization, and compound interaction screening.
Applications
Quantification of UGT enzymatic activity, screening for enzyme inhibitors or activators, assessment of glucuronidation rates, metabolic interaction studies, and ADME characterization in microsomal or recombinant systems.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Target
UDP-glucuronosyltransferase (UGT) enzymes
Detection Method
Fluorescent
Sample Type
Tissue, suspension cells, microsomes, adherent cells
Assay Measures
Quantitative
Research Areas
Drug metabolism & pharmacokinetics (ADME), pharmacology, toxicology, enzymology, medicinal chemistry, xenobiotic metabolism, etc.
Size
100 tests
Data Output Type
Quantitative fluorescence-based measurement of glucuronidation activity using kinetic or endpoint detection.
LOD
= 0.1 mU/well
Species
General (All species)
Assay Measures
Quantitative
Storage
Upon receipt, store the kit in accordance with the storage conditions specified in the product manual.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to -20°C; storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
12 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
UDP-glucuronosyltransferases (UGTs) are key Phase II metabolic enzymes responsible for conjugating glucuronic acid to diverse endogenous molecules and xenobiotics. This glucuronidation process enhances compound solubility and facilitates elimination through biliary or renal excretion. Because UGT enzymes metabolize numerous therapeutic agents, their activity plays a central role in determining drug exposure, efficacy, and safety.
Pathways
UGT enzymes function within the Phase II xenobiotic metabolism pathway, catalyzing glucuronidation reactions using UDP-glucuronic acid as a cofactor. These conjugation reactions typically follow Phase I oxidation processes mediated by cytochrome P450 enzymes. Together, these sequential metabolic steps regulate drug detoxification, clearance, and potential drug-drug interactions.
For Research Use Only | Not For Clinical Use
Online Inquiry